#ASCOGI25 
Based on the data from ESMO24 and ASCO GI 2025, the DESTINY-Gastric03 study demonstrated that in first-line gastric/GEJ cancer, lowering the T-DXd dose to 5.4 mg/kg and reducing the initial capecitabine dose improved safety while maintaining efficacy, as measured by ORR and PFS.
#ASCOGI25